

A1 & 365(c) from co-pending patent application PCT/EP98/08169 filed on December 16, 1998 designating the United States of America, which itself claims priority from European Patent Application EP 97203974.7 filed on December 17, 1997."

IN THE CLAIMS:

C1
A2
3. (Amended) [A]The peptide [according to]of claim 1 [or 2] exhibiting trypanolytic activity [preferably in combination with cytolytic and/or glucan binding and/or LPS binding and/or opsonizing activity].

4. (Amended) An antibody specifically recognizing [the]a peptide [of any of the preceding claims or]selected from the group consisting of a peptide comprising at least 9 contiguous amino acids of SEQ.ID.NO.1, a peptide comprising the amino acid sequence of SEQ.ID.NO.3, a fragment [or]of either thereof, and an epitope of either thereof.

C1
A3
6. (Amended) A recombinant expression vector comprising [a]the DNA sequence [according to]of claim 5.

C1
A4
8. (Amended) The host cell of claim 7 wherein the host cell is selected from the group consisting of *E. [Coli]coli*, *Bacillus sp.*, *Streptomyces sp.*, yeast, fungi, insect cells, plant cells [or]and mammalian cells.

C1
A5
10. (Amended) A [method]process for the production of an *Eisenia foetida* polypeptide or an immunologically active or functional fragment thereof comprising culturing a host cell of claim 7[, 8 or 9] under conditions allowing the expression and production of said polypeptide and recovering the thus produced polypeptide from the culture.

11. (Amended) A pharmaceutical composition comprising at least a peptide [according to claim 1, 2 or 3]selected from the group of peptides consisting of a peptide comprising at least 9

LI
A6
contiguous amino acids of SEQ.ID.NO.1, a peptide comprising the amino acid sequence of SEQ.ID.NO.3, a fragment of either thereof, and an epitope of either thereof.

C)
A7
12. (Amended) [Use of]A method of treating a disease selected from the group of diseases consisting of trypanosomal infection, bacterial infection and cancer, said method comprising:

administering a peptide [according to claim 1, 2 or 3 for the preparation of a medicament to treat trypanosomal infection, bacterial infection or cancer]selected from the group of peptides consisting of a peptide comprising at least 9 contiguous amino acids of SEQ.ID.NO.1, a peptide comprising the amino acid sequence of SEQ.ID.NO.3, a fragment of either thereof, and an epitope of either thereof..

09556101 10931600
A8
Please add the following new claims:

13. The peptide of claim 2 exhibiting trypanolytic activity.

14. The process according to claim 10, wherein the host cell is selected from the group consisting of *E. coli*, *Bacillus sp.*, *Streptomyces sp.*, yeast, fungi, insect cells, plant cells, and mammalian cells.

15. The process according to claim 14, wherein the host cell is *E. coli*.

16. The pharmaceutical composition of claim 11 wherein the peptide comprises at least 9 contiguous amino acids of SEQ.ID.NO.1 a fragment thereof, or an epitope thereof.

17. The pharmaceutical composition of claim 11 wherein the peptide comprises the amino acid sequence of SEQ.ID.NO.3, a fragment thereof, or an epitope thereof.

18. The method according to claim 12 wherein the peptide comprises at least 9